Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motion Serifos
NCT05903924Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tradipitant in motion sickness (3 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Prevention of Vomiting Measured by Vomiting Assessment (VA) at 1 day. Started Sep 2023; status: completed.
02
Drugs
tradipitant
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT05903924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903924.